We kindly request that you define your field(s) of interest and your number of diagnoses for each separate urological pathology through an on-line questionnaire.

Please click here to join the EAU as an investigator now!

We look forward to receiving your contribution.

Surveys from Centerwatch - an organisation which provides information to the clinical trial industry - indicate that more than 50% of the delays in phase II-III clinical trials are caused by poor patient recruitment. On top of that, 80% of all clinical trials experience enrolment delays. Organisations currently involved in conducting clinical phase II-III trials have not been able to improve patient recruitment.

The key to successfully promote a quicker introduction and development of new treatments is to improve the efficiency of the clinical trial process at centres (sites) - this is where the clinical research activities take place.

To meet this need for committed and high-output, high-quality investigators -both in industrial (pharmaceutical and medical device) and non-industrial research - the EAU has set up a clinical trialists' database.

Naturally it is of key importance to improve patient recruitment. The EAU aims to improve current standard as well as to improve the overall standard of clinical research in European urology across a wide range of subspecialty areas in order to be able to advise on the design of clinical trials and to participate in clinical trials. The EAU  Research Foundation needs a better overview of the potential of European urologists. In the database, characteristics are collected from European urological centres and institutions interested in participating in clinical trials managed by the Central Research Office.This clinical trialists database may serve as a tool, to be consulted by you and us, in case the Foundation receives initial feasibility questions for clinical trials.Should your centre participate in a trial (now or in the future), the EAU hopes to be able to track several key performance indicators (time to ethical committee approval, percentage of recruited vs. committed patients, number of queries etc). It also aims to identify and select potential investigators who will enable us to speed up the clinical trialing process, recruit patients faster, and more efficiently and effectively deliver the highest quality patient data. This way the EAU will become a reliable partner for sponsors (e.g. pharmaceutical companies, medical equipment manufacturers and non-industrial organisations) in conducting multi-centre phase II-III clinical trials.

This database will eventually help us reach one of our major goals, which is to efficiently organise the clinical trialing process, both centrally and locally. The result will hopefully be that new treatments, drugs and technology will become available to our patients soon.

Contact:
EAU Central Research Office
Wim P.J. Witjes, MD, PhD
Clinical Research Director
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands
F. +31-26-389 06 79
E. w.witjes@curatrial.com